Protective Effect of Curcumin on Liver Damage Induced by Biliary Obstruction in Rats

Year 2011, Volume: 2011 Issue: 4, 352 - 357, 01.04.2011

Cengiz Erenoğlu Mehmet Kanter Burhan Aksu Tamer Sağıroğlu Süleyman Ayvaz Cevat Aktaş Mustafa Erboğa

https://doi.org/10.5174/tutfd.2010.04312.1

Abstract

Objective: The aim of this study is to evaluate the possible protective effects of curcumin against cholestatic oxidative stress and liver damage in common bile duct ligated rats. Material and Methods: A total of 18 male Wistar albino rats were divided into three groups: control, common bile duct ligation (BDL) and BDL+curcumin. Each group contained 6 animals. The rats in the curcumin treated group were given curcumin (100 mg/kg) once a day orally for 14 days, starting 3 days prior to BDL operation. Following 14 days of treatment, all the animals were decapitated and liver tissue samples were obtained for histopathological investigation. Results: The changes demonstrating the bile duct proliferation and fibrosis in expanded portal tracts, including the extension of proliferated bile ducts into lobules, mononuclear cells, and neutrophil infiltration into the widened portal areas, were observed in BDL group. Treatment of BDL with curcumin attenuated liver damage. Both the elevated alpha smooth muscle actin (α-SMA), and the activity of TUNEL in the BDL were observed to be reduced with the curcumin treatment. Conclusion: Our data indicate that curcumin reduced BDL-induced cholestatic liver injury, bile duct proliferation, fibrosis.

Keywords

Curcumin, immunohistochemistry, TUNEL, liver, bile duct ligation

Protective Effect of Curcumin on Liver Damage Induced by Biliary Obstruction in Rats

Abstract

References

• Maher JJ, McGuire RF. Extracellular matrix gene expression in- creases preferentially in rat lipocytes and sinusoidal endothelial cells during hepatic fibrosis in vivo. J Clin Invest 1990; 86:1641-8.
• Morris JS, Gallo GA, Scheuer PJ, Sherlock S. Percutaneous liver biopsy in patients with large bile duct obstruction. Gastroenterol- ogy 1975;68:750-4. [CrossRef]
• Liu TZ, Lee KT, Chern CL, Cheng JT, Stern A, Tsai LY. Free radical triggered hepatic injury of experimental obstructive jaundice of rats involves overproduction of proinflammatory cytokines and enhanced activation of nuclear factor kappab. Ann Clin Lab Sci 2001;31:383-90.
• Kountouras J, Billing BH, Scheuer PJ. Prolonged bile duct ob- struction: a new experimental model for cirrhosis in the rat. Br J Exp Pathol 1984;65:305-11.
• Benedetti A, Alvaro D, Bassotti C, Gigliozzi A, Ferretti G, La Rosa T, et al. Cytotoxicity of bile salts against biliary epithelium: a study in isolated bile ductule fragments and isolated perfused rat liver. Hepatology 1997;26:9-21. [CrossRef]
• Kanter M, Yener Z. A rabbit model for liver fibrosis. Scand J Lab Anim Sci 2001;28:213-23.
• Strimpakos AS, Sharma RA. Curcumin: preventive and therapeu- tic properties in laboratory studies and clinical trials. Antioxid Re- dox Signal 2008;10:511-45. [CrossRef]
• Punithavathi D, Venkatesan N, Babu M. Curcumin inhibition of bleomycin-induced pulmonary fibrosis in rats. Br J Pharmacol 2000;131:169-72. [CrossRef]
• Kim KM, Pae HO, Zhung M, Ha HY, Ha YA, Chai KY, et al. Involve- ment of anti-inflammatory heme oxygenase-1 in the inhibitory effect of curcumin on the expression of proinflammatory induc- ible nitric oxide synthase in RAW264.7 macrophages. Biomed Pharmacother 2008;62:630-6. [CrossRef]
• Misko TP, Moore WM, Kasten TP, Nickols GA, Corbett JA, Tilton RG. Selective inhibition of the inducible nitric oxide synthase by aminoguanidine. Eur J Pharmacol 1993;233:119-25. [CrossRef]
• Jian MY, Koizumi T, Kubo K. Effects of nitric oxide synthase inhibi- tor on acid aspiration-induced lung injury in rats. Pulm Pharmacol Ther 2005;18:33-9. [CrossRef]
• Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepa- tol 1995;22:696-9. [CrossRef]
• Hsu SM, Raine L, Fanger H. Use of avidin biotin-peroxidase complex (ABC) in immunperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J His- tochem Cytochem 1981;29:577-80. [CrossRef]
• Schmitt-Graff A, Kruger S, Bochard F, Gabbiani G, Denk H. Mod- ulation of alpha smooth muscle actin and desmin expression in perisinusoidal cells of normal and diseased human livers. Am J Pathol 1991;138:1233-42.
• Tracy TF Jr, Fox ES. Molecular and cellular control points in pedi- atric liver injury and repair. Semin Pediatr Surg 1996;5:175-81.
• Roggin KK, Kim JC, Kurkchubasche AG, Papa EF, Vezeridis AM, Tracy TF. Macrophage phenotype during cholestatic injury and repair: the persistent inflammatory response. J Pediatr Surg 2001;36:220-8. [CrossRef]
• Strazzabosco M, Fabris L, Spirli C. Pathophysiology of cholangi- opathies. J Clin Gastroenterol 2005;39:90-102. [CrossRef]
• Marley R, Holt S, Fernando B. Lipoic acid prevents development of the hyperdynamic circulation in anesthetized rats with biliary cirrhosis. Hepatology 1999;29:1358-63. [CrossRef]
• Karaman A, Iraz M, Kirimlioglu H, Karadag N, Tas E, Fadillioglu E. Hepatic damage in biliary obstructed rats is ameliorated by leflu- nomide treatment. Pediatr Surg Int 2006;22:701-8. [CrossRef]
• Parola M, Leonarduzzi G, Robino G, Albano E, Poli G, Dianzani MU. On the role of lipid peroxidation in the pathogenesis of liver damage induced by long-standing cholestasis. Free Radic Biol Med 1996;20:351-9. [CrossRef]
• Kullak-Ublick GA, Meier PJ. Mechanisms of cholestasis. Clin Liver Dis 2000;4:357-85. [CrossRef]
• Baghdasaryan A, Claudel T, Kosters A, Gumhold J, Silbert D, Thüring- er A, et al. Curcumin improves sclerosing cholangitis in Mdr2-/- mice by inhibition of cholangiocyte inflammatory response and portal myofibroblast proliferation. Gut 2010;59:521-30. [CrossRef]
• Reyes-Gordillo K, Segovia J, Shibayama M, Tsutsumi V, Ver- gara P, Moreno MG, et al. Curcumin prevents and reverses cir- rhosis induced by bile duct obstruction or CCl4 in rats: role of TGF-b modulation and oxidative stres. Fundam Clin Pharmacol 2008;22:417-27. [CrossRef]
• Serviddio G, Pereda J, Pallardo FV, Carretero J, Borras C, Cutrin J, et al. Ursodeoxycholic acid protects against secondary biliary cirrhosis in rats by preventing mitochondrial oxidative stress. Hepatology 2004;39:711-20. [CrossRef]
• Friedman SL. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem 2000;275:2247-50. [CrossRef]
• Nan JX, Park EJ, Kim HJ, Ko G, Sohn DH. Antifibrotic effects of the methanol extract of Polygonum aviculare in fibritic rats induced by bile duct ligation and scission. Biol Pharm Bull 2000;23:240-3. [CrossRef]
• Miyazaki H, Van Eyken P, Roskams T, De Vos R, Desmet VJ. Tran- sient expression of tenascin in experimentally induced cholestat- ic fibrosis in rat liver: an immunohistochemical study. J Hepatol 1993;19:353-66. [CrossRef]
• Bolt MJ, Sitrin MD, Favus MJ, Rosenberg IH. Hepatic vitamin D 25- hydroxylase: inhibition by bile duct ligation or bile salts. Hepatology 1981;1:436-40. [CrossRef]
• Akiyoshi H, Terada T. Mast cell, myofibroblast and nerve terminal complexes in carbon tetrachloride-induced cirrhotic rat livers. J Hepatol 1998;29:112-9. [CrossRef]
• Rajagopalan R, Sridharana S, Menon VP. Hepatoprotective role of bis-demethoxy curcumin analog on the expression of matrix metalloproteinase induced by alcohol and polyunsaturated fatty acid in rats. Toxicol Mech Methods 2010;20:252-9. [CrossRef]
• Aksu B, Umit H, Kanter M, Guzel A, Aktas C, Civelek S, et al. Ef- fects of methylene blue in reducing cholestatic oxidative stress and hepatic damage after bile-duct ligation in rats. Acta Histo- chem 2010;112:259-69. [CrossRef]
• Ogata Y, Takahashi M, Takeuchi K, Ueno S, Mano H, Ookawara S, et al. Fluvastatin induces apoptosis in rat neonatal cardiac myo- cytes: a possible mechanism of statin-attenuated cardiac hyper- trophy. J Cardiovasc Pharmacol 2002;40:907-15. [CrossRef]
• Soma MR, Gabbiani G, Fumagalli R, et al. Relationship between mevalonate pathway and arterial myocyte proliferation: in vitro studies with inhibitors of HMG-CoA reductase. Atherosclerosis 1993;101:117-25. [CrossRef]